Semax

Semax Cognitive & Nootropic Overview

Semax is a meticulously engineered neurotrophic compound, designed to heavily bias central nervous activity toward synaptic growth, neuronal protection, and optimized cerebral signaling efficiency.

Physiochemical Profile

Parameter	Value
Molecular Formula	C39H51N13O15
Molecular Mass	941.9 g/mol
Assay Purity	>98.5%
Appearance	White crystalline powder

Figure 1: Semax Blood-Brain Barrier (BBB) Permeation

Cerebral Mechanism of Action

Detailed cascade of actions triggering its primary nootropic effects:

1. A synthetic heptapeptide analogue of Adrenocorticotropic Hormone (ACTH 4-10).
2. Lacks the vast endocrine side effects of standard systemic ACTH.
3. Modulates the density and conformation of critical dopamine and serotonin receptors.
4. Dramatically upregulates Brain-Derived Neurotrophic Factor (BDNF) primarily within the hippocampus.
5. Reduces oxidative stress through localized CNS antioxidant pathways.

Figure 2: Rate of Synaptogenesis / BDNF Expression

Primary Research Outcomes

• Finding 1: Extensively utilized to boost acute concentration, focus, and rapid cognitive shifting.
• Finding 2: Accelerates the acquisition rate of new fine motor skills in mammalian models.
• Finding 3: Helps preserve nervous system function in profoundly stressful environmental conditions.

ACTH(4-10) Analogue & Neurotrophic Signaling

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the ACTH(4-10) fragment, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike full-length ACTH, Semax retains the nootropic and neuroprotective properties of the 4-10 fragment while lacking any steroidogenic (cortisol-stimulating) activity. Its primary mechanism involves activation of the BDNF/TrkB signaling axis and modulation of monoamine neurotransmitter systems, producing cognitive enhancement without the endocrine disruption of corticotropin-based therapies.

1. Semax upregulates BDNF (brain-derived neurotrophic factor) expression in the hippocampus and prefrontal cortex through CREB phosphorylation via the Ras/ERK/MAPK cascade.
2. Elevated BDNF activates TrkB receptors, promoting dendritic branching, spine formation, and long-term potentiation (LTP)—the cellular substrate of learning and memory.
3. NGF (nerve growth factor) and GDNF (glial-derived neurotrophic factor) expression are simultaneously increased, providing broad neurotrophic support.
4. Serotonin and dopamine turnover in the prefrontal cortex is enhanced, improving attention, working memory, and executive function.
5. Semax inhibits enkephalinase, prolonging the activity of endogenous enkephalins and contributing to anxiolytic and stress-buffering effects.

Clinical Use & Russian Regulatory Status

• Approved Indications: Semax is approved in Russia and several CIS countries as a nasal spray (0.1% and 1% solutions) for stroke recovery, cognitive impairment, optic nerve atrophy, and ADHD in children.
• Stroke Research: In ischemic stroke patients, intranasal Semax (1%, 12 mg/day) administered within 6 hours improved NIHSS scores and reduced infarct volume on follow-up MRI.
• Administration: Intranasal delivery provides rapid CSF access via the olfactory nerve pathway, bypassing the blood-brain barrier. Peak brain concentrations within 5–10 minutes.
• Safety: Extensive clinical use in Russia (since 1994) with no significant adverse effects reported. No tolerance development observed with chronic use.
• Half-Life: Semax has a short plasma half-life (~3 minutes) but prolonged central effects (4–24 hours) due to neurotrophic gene expression changes that outlast the peptide’s presence.